Bibliographic Details
| Title: |
The protective effect of tumor necrosis factor-alpha inhibitors in COVID-19 in patients with inflammatory rheumatic diseases compared to the general population—A comparison of two German registries |
| Authors: |
Rebecca Hasseli, Frank Hanses, Melanie Stecher, Christof Specker, Tobias Weise, Stefan Borgmann, Martina Hasselberger, Bernd Hertenstein, Martin Hower, Bimba F. Hoyer, Carolin Koll, Andreas Krause, Marie von Lilienfeld-Toal, Hanns-Martin Lorenz, Uta Merle, Susana M. Nunes de Miranda, Mathias W. Pletz, Anne C. Regierer, Jutta G. Richter, Siegbert Rieg, Christoph Roemmele, Maria M. Ruethrich, Tim Schmeiser, Hendrik Schulze-Koops, Anja Strangfeld, Maria J.G.T. Vehreschild, Florian Voit, Reinhard E. Voll, Jörg Janne Vehreschild, Ulf Müller-Ladner, Alexander Pfeil |
| Source: |
Frontiers in Medicine, Vol 11 (2024) |
| Publisher Information: |
Frontiers Media S.A., 2024. |
| Publication Year: |
2024 |
| Collection: |
LCC:Medicine (General) |
| Subject Terms: |
inflammatory rheumatic diseases, COVID-19, general population, tumor necrosis factor-alpha inhibitors, severe disease, Medicine (General), R5-920 |
| More Details: |
ObjectivesTo investigate, whether inflammatory rheumatic diseases (IRD) inpatients are at higher risk to develop a severe course of SARS-CoV-2 infections compared to the general population, data from the German COVID-19 registry for IRD patients and data from the Lean European Survey on SARS-CoV-2 (LEOSS) infected patients covering inpatients from the general population with SARS-CoV-2 infections were compared.Methods4310 (LEOSS registry) and 1139 cases (IRD registry) were collected in general. Data were matched for age and gender. From both registries, 732 matched inpatients (LEOSS registry: n = 366 and IRD registry: n = 366) were included for analyses in total.ResultsRegarding the COVID-19 associated lethality, no significant difference between both registries was observed. Age > 65°years, chronic obstructive pulmonary disease, diabetes mellitus, rheumatoid arthritis, spondyloarthritis and the use of rituximab were associated with more severe courses of COVID-19. Female gender and the use of tumor necrosis factor-alpha inhibitors (TNF-I) were associated with a better outcome of COVID-19.ConclusionInflammatory rheumatic diseases (IRD) patients have the same risk factors for severe COVID-19 regarding comorbidities compared to the general population without any immune-mediated disease or immunomodulation. The use of rituximab was associated with an increased risk for severe COVID-19. On the other hand, the use of TNF-I was associated with less severe COVID-19 compared to the general population, which might indicate a protective effect of TNF-I against severe COVID-19 disease. |
| Document Type: |
article |
| File Description: |
electronic resource |
| Language: |
English |
| ISSN: |
2296-858X |
| Relation: |
https://www.frontiersin.org/articles/10.3389/fmed.2024.1332716/full; https://doaj.org/toc/2296-858X |
| DOI: |
10.3389/fmed.2024.1332716 |
| Access URL: |
https://doaj.org/article/826148ec9ab2440794ff1f5021a13811 |
| Accession Number: |
edsdoj.826148ec9ab2440794ff1f5021a13811 |
| Database: |
Directory of Open Access Journals |
